National Cancer Institute (NCI): Mixed Tumor, Mullerian trials

The registry lists 11 Mixed Tumor, Mullerian studies with National Cancer Institute (NCI) as lead sponsor. 0 are open to participants now and 9 have results posted.

Phase 1 2Phase 2 10(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• Pazopanib Hydrochloride in Treating Patients With Recurrent or Persistent Uterine CancerCompletedNCT01247571Phase 2Results posted
• Ixabepilone in Treating Patients With Recurrent or Persistent Uterine CancerCompletedNCT01168232Phase 2Results posted
• Temsirolimus in Treating Patients With Recurrent or Persistent Cancer of the UterusTerminatedNCT01061606Phase 2Results posted
• Temsirolimus and Bevacizumab in Treating Patients With Advanced Endometrial, Ovarian, Liver, Carcinoid, or Islet Cell CancerCompletedNCT01010126Phase 2Results posted
• Sunitinib Malate in Treating Patients With Recurrent or Metastatic Endometrial CancerCompletedNCT00478426Phase 2Results posted
• Ziv-aflibercept in Treating Patients With Locally Advanced, Unresectable, or Metastatic Gynecologic Soft Tissue SarcomaCompletedNCT00390234Phase 2Results posted
• Sorafenib in Treating Patients With Advanced or Recurrent Uterine CancerCompletedNCT00238121Phase 2Results posted
• Imatinib Mesylate in Treating Patients With Recurrent or Persistent Uterine CancerCompletedNCT00075400Phase 2Results posted
• Thalidomide in Treating Patients With Recurrent or Persistent Carcinosarcoma of the UterusCompletedNCT00025506Phase 2Results posted
• Testing the Addition of ASTX660 (Tolinapant) to the Usual Chemotherapy Treatment (Paclitaxel With or Without Bevacizumab) in Patients With Recurrent Ovarian CancerWithdrawnNCT06393751Phase 1/2
• Carboplatin, Paclitaxel, Bevacizumab, and Veliparib in Treating Patients With Newly Diagnosed Stage II-IV Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal CancerCompletedNCT00989651Phase 1